PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: A genetic study of six cohorts

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Rodriguez Rodriguez, Luis ^a   Ivorra Cortes, Jose ^b   Carmona, F David ^c   Martín, Javier ^c   Balsa, Alejandro ^d   van Steenbergen, Hanna W ^e   van der Helm van Mil, Annette H M ^e   González Álvaro, Isidoro ^f   Fernandez Gutiérrez, Benjamín ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Polymorphism; PTGER4; Radiological joint damage; Rheumatoid arthritis; Rs76523431

Indexed keywords

PROSTAGLANDIN E RECEPTOR 4; PTGER4 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE DOSAGE; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; PLEIOTROPY; PTGER4 GENE; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; DIAGNOSTIC IMAGING; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY;

ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOGRAPHY; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RISK FACTORS;

EID: 84946401247     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0830-z     Document Type: Article

References (52)

1. Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005;19:137-46.
2. Radner H, Smolen JS, Aletaha D. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011;50:381-8.
3. van Nies JAB, Krabben A, Schoones JW, Huizinga TWJ, Kloppenburg M, van der Helm-van Mil AHM. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73:861-70.
4. 2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol. 2002;136:287-95.
5. 2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med. 2006;203:325-35.
6. 2 in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis. J Immunol. 2007;178:8138-47.
7. H17 cell expansion. Nat Med. 2009;15:633-40.
8. 4 receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010;160:292-310.
9. Evans DM, Spencer CCA, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43:761-7.
10. 2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest. 2002;110:651-8.
11. Yoshida K, Oida H, Kobayashi T, Maruyama T, Tanaka M, Katayama T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A. 2002;99:4580-5.
12. Ono K, Akatsu T, Kugai N, Pilbeam CC, Raisz LG. The effect of deletion of cyclooxygenase-2, prostaglandin receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by mouse mammary cancer cell lines. Bone. 2003;33:798-804.
13. 2 receptor impairs osteoclastogenesis in vitro. Endocrinology. 2000;141:2054-61.
14. Yoshida T, Horiuchi T, Sakamoto H, Inoue H, Takayanagi H, Nishikawa T, et al. Production of parathyroid hormone-related peptide by synovial fibroblasts in human osteoarthritis. FEBS Lett. 1998;433:331-4.
15. Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17:R116-21.
16. De Jager PL, Jia X, Wang J, de Bakker PIW, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41:776-82.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
18. Rodriguez-Rodriguez L, Jover-Jover JA, Fontsere O, Peña-Blanco RC, León L, Fernández-Gutierrez B, et al. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis. Scand J Rheumatol. 2013;42:433-6.
19. González-Álvaro I, Ortiz AM, Alvaro-Gracia JM, Castañeda S, Díaz-Sánchez B, Carvajal I, et al. Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis. PLoS One. 2011;6:e29492.
20. Richi P, Balsa A, Muñoz-Fernández S, Villaverde V, Fernández-Prada M, Vicario JL, et al. Factors related to radiological damage in 61 Spaniards with early rheumatoid arthritis. Ann Rheum Dis. 2002;61:270-2.
21. de Rooy DPC, van der Linden MPM, Knevel R, Huizinga TWJ, van der Helm-van Mil AHM. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50:93-100.
22. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-7.
23. Wolfe F, Michaud K. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford). 2011;50:16-24.
24. Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011;13:101.
25. de Rooy DPC, Zhernakova A, Tsonaka R, Willemze A, Kurreeman BAS, Trynka G, et al. A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2014;73:1163-9.
26. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790-7.
27. Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C, Kettunen J, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45:1238-43.
28. van der Helm-van Mil AHM, Knevel R, van der Heijde D, Huizinga TWJ. How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis? Rheumatology (Oxford). 2010;49:1429-35.
29. Knevel R, Tsonaka R, le Cessie S, van der Linden MPM, Huizinga TWJ, van der Heijde DMFM, et al. Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scand J Rheumatol. 2013;42:182-9.
30. Strand V, Landéwé R, van der Heijde D. Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. Ann Rheum Dis. 2002;61 Suppl 2:ii64-6.
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
32. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014;13:668-77.
33. Chai W, Lian Z, Chen C, Liu J, Shi LL, Wang Y. JARID1A, JMY, and PTGER4 polymorphisms are related to ankylosing spondylitis in Chinese Han patients: a case-control study. PLoS One. 2013;8:e74794.
34. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-24.
35. Julià A, Domènech E, Ricart E, Tortosa R, García-Sánchez V, Gisbert JP, et al. A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut. 2013;62:1440-5.
36. Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-25.
37. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-78.
38. Perdigones N, Martín E, Robledo G, Lamas JR, Taxonera C, Díaz-Rubio M, et al. Study of chromosomal region 5p13.1 in Crohn's disease, ulcerative colitis, and rheumatoid arthritis. Hum Immunol. 2010;71:826-8.
39. Weersma RK, Stokkers PCF, Cleynen I, Wolfkamp SCS, Henckaerts L, Schreiber S, et al. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol. 2009;104:630-8.
40. Glas J, Seiderer J, Czamara D, Pasciuto G, Diegelmann J, Wetzke M, et al. PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites. PLoS One. 2012;7:e52873.
41. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-62.
42. Kenny EE, Pe'er I, Karban A, Ozelius L, Mitchell AA, Ng SM, et al. A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet. 2012;8:e1002559.
43. Peter I, Mitchell AA, Ozelius L, Erazo M, Hu J, Doheny D, et al. Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet. 2011;12:63.
44. Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet. 2007;3:e58.
45. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596-604.
46. Latiano A, Palmieri O, Latiano T, Corritore G, Bossa F, Martino G, et al. Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One. 2011;6:e22688.
47. McGovern DPB, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet. 2010;42:332-7.
48. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-52.
49. Matesanz F, González-Pérez A, Lucas M, Sanna S, Gayán J, Urcelay E, et al. Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. PLoS One. 2012;7:e36140.
50. Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, Moutsianas L, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-9.
51. SNP Annotation and Proxy Search. https://www.broadinstitute.org/mpg/snap/doc.php.
52. miRBase: the microRNA database. http://www.mirbase.org/search.shtml.